This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Intercept Pharmaceuticals Appoints Daniel Regan As Chief Commercial Officer

NEW YORK, March 4, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the appointment of Daniel P. Regan to the newly created position of Chief Commercial Officer. Mr. Regan is a seasoned commercial executive bringing more than 20 years of pharmaceutical and biotechnology industry experience to the company.

Mr. Regan joins Intercept from Inspiration Biopharmaceuticals where he served as Chief Commercial Officer. Prior to Inspiration, he held positions of increasing responsibility over a 12 year tenure at Genzyme Corporation where he led multi-functional teams in sales, marketing and commercialization, and launched several new products into both established and smaller emerging markets. In his last position, Mr. Regan served as General Manager, Senior Vice President of the U.S. Personalized Genetic Health business, where he was responsible for the U.S. rare disease franchise. Previously, Mr. Regan was the global General Manager, Senior Vice President of the Renal franchise at Genzyme, where he was responsible for the launch of Renagel and Renvela in the U.S. and internationally, as well as for the continued development and expansion of the Hectorol franchise. In addition to his domestic experience, Mr. Regan has worked extensively in the European, Latin American and Asia Pacific markets. Prior to Genzyme, he held sales and marketing positions at Janssen Pharmaceutica, a pharmaceutical division of Johnson & Johnson.

"Dan is a proven business leader with invaluable experience in commercial strategy, marketing and general management," commented Mark Pruzanski M.D., President and CEO of Intercept. "His knowledge of the evolving U.S. and European markets and his success in the global commercialization of novel therapeutics for rare orphan and more prevalent specialty indications will serve us well as we prepare for the anticipated approval and launch of OCA."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs